The Myriad Neuroscience Scientific Advisory Board guides continuing innovation of GeneSight® technology.
Andrew Nierenberg, M.D., Chair
Dr. Nierenberg is the director of the Dauten Family Center for Bipolar Treatment Innovation, associate director of the Depression Clinical and Research Program, and director of the Center for Clinical Research Education at Massachusetts General Hospital, where he holds the Thomas P. Hackett, MD, Endowed Chair in Psychiatry. He has published more than 470 papers and was recognized among the World’s Most Influential Scientific Minds 2014-2017 by Thompson Reuters for being in the top 1% of literature citations in psychiatry/ psychology worldwide. He received the Depression Bipolar Support Alliance Gerald L. Klerman Young and Senior Investigator Awards, as well as the Brain and Behavior Foundation Colvin Prize for outstanding achievement in mood disorders research. He is on the editorial boards of multiple psychiatric journals, including serving as editor in chief of Psychiatric Annalsand deputy editor of Depression and Anxiety.
Boadie W. Dunlop, M.D.
Dr. Dunlop is associate professor and director of the Mood and Anxiety Disorders Program at Emory University. His clinical research is focused on the neurobiology, psychopharmacology, and the personalized treatment of major depression, bipolar, post-traumatic stress, and anxiety disorders. He has served as an investigator for more than 70 clinical studies of medication and psychotherapy treatments for these conditions. He is currently the principal investigator of two National Institute of Mental Health grants examining neuroimaging and metabolomic predictors of outcome to treatments for major depressive disorder. Dr. Dunlop has authored approximately 100 research papers on mental health topics.
James L. Kennedy, M.D., FRCP(C), FRSC
Dr. Kennedy is head of molecular science and the Tanenbaum Centre for Pharmacogenetics in the Campbell Family Mental Health Research Institute at the Centre for Addiction and Mental Health in Toronto. Dedicated to finding genes involved in the cause of mental illness, he has published pioneering findings relating gene variants in the dopamine, serotonin, and neurodevelopment systems to psychiatric disorders and to treatment response. Dr. Kennedy has led investigations using powerful DNA sequencing technology to understand genetic variation and function. In addition, Dr. Kennedy is investigating genetic factors that may predict response to and side effects of psychiatric medications (pharmacogenetics). Dr. Kennedy has published more than 650 peer-reviewed scientific articles with more than 25,000 citations. He is a member of the Royal Society of Canada, the highest academic recognition in Canada.
Lawrence J. Lesko, Ph.D., FCP
Dr. Lesko is emeritus professor and founding director of the Center for Pharmacometrics and Systems Pharmacology at the University of Florida College of Pharmacy. He is board certified in clinical pharmacology and is a registered pharmacist. Dr. Leskowas the first director of the Office of Clinical Pharmacology (OCP) in the Center for Drug Evaluation and Research at the FDA. There, he chaired the Clinical Pharmacology Coordinating Subcommittee and authored or co-authored numerous Guidance for Industry documents. He led the advancement of precision medicine through the update of labels of previously approved drugs with new genetic information on safety, dosing and efficacy. Dr. Lesko has published more than 200 peer-reviewed manuscripts and is a frequent national and international speaker.He received the first FDA OCP Distinguished Alumni Lectureship Award for his contributions to clinical pharmacology and has been recognized with many other industry honors.
Erika L. Nurmi, M.D.
Dr. Erika Nurmi is the medical director of the UCLA Obsessive-Compulsive Disorder Intensive Outpatient Program, the associate director of the psychiatry residency research track, and a member of the Child and Adolescent Psychiatry Division faculty in the Department of Psychiatry and Biobehavioral Sciences at the UCLA Semel Institute for Neuroscience and Human Behavior. Dr. Nurmi’s research focuses the genetic basis of childhood OCD and tic disorders. With Dr. James McCracken, she is investigating pharmacogenomic factors in the treatment of autism, ADHD, anxiety, and depression. She also collaborates with Dr. Edythe London in examining genetic predictors of substance abuse phenotypes.
Cathryn Lewis, PhD
Cathryn Lewis, PhD, is Professor of Genetic Epidemiology & Statistics at King’s College London, and Head of Department at the Social, Genetic and Developmental Psychiatry Centre (Sept 2019). Her academic training is in statistics, and she has been analysing genetic studies since her PhD. She co-chairs the Major Depressive Disorder Working group of the Psychiatric Genomics Consortium,and leads the NIHR Maudsley Biomedical Research Centre Biomarkers and Genomics theme. She has published over 300 papers on statistical genetics methodology and analysis. Her research identifies and characterises genetic variants associated with human disease, including depression, schizophrenia, stroke and in pharmacogenetics. A major research focus is risk assessment, determining how the polygenic component of mental health disorders can be measured accurately and communicated effectively.
Title: Head of Department at the Social, Genetic and Developmental Psychiatry Centre
Academic Affiliation: King’s College London